TY - JOUR
T1 - Nrf2 activation for kidney disease treatment—a mixed blessing?
AU - Nezu, Masahiro
AU - Suzuki, Norio
N1 - Funding Information:
NS is supported by the Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine (INGEM).
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2021/1
Y1 - 2021/1
N2 - Activation of cellular antioxidative signaling is expected to be a silver bullet against kidney diseases, and clinical trials of compounds activating the antioxidant transcription factor Nrf2 have revealed their renoprotective effects. However, cardiac events have been observed in some cases with elevated urinary albumin excretion in these trials. Therefore, elucidating the negative effects of Nrf2 activation is essential. Rush and colleagues demonstrated that Nrf2 activation aggravates podocyte injury, a factor related to proteinuria and cardiac failure.
AB - Activation of cellular antioxidative signaling is expected to be a silver bullet against kidney diseases, and clinical trials of compounds activating the antioxidant transcription factor Nrf2 have revealed their renoprotective effects. However, cardiac events have been observed in some cases with elevated urinary albumin excretion in these trials. Therefore, elucidating the negative effects of Nrf2 activation is essential. Rush and colleagues demonstrated that Nrf2 activation aggravates podocyte injury, a factor related to proteinuria and cardiac failure.
UR - http://www.scopus.com/inward/record.url?scp=85098587491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098587491&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.08.033
DO - 10.1016/j.kint.2020.08.033
M3 - Comment/debate
C2 - 33390228
AN - SCOPUS:85098587491
SN - 0085-2538
VL - 99
SP - 20
EP - 22
JO - Kidney International
JF - Kidney International
IS - 1
ER -